{"id":"aa1de190-68cf-5809-8bc6-9122a757d581","stable_key":"31b1baa4-4113-5541-b9e7-fe44a5253a07:scope-oseltamivir","predicate":"has_distinct_compound_or_preparation_comparison","statement":"The oseltamivir record is a distinct-compound or preparation comparison; its biological effects are not assigned to isolated shikimic acid.","claim_class":"identity","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"ce19429d-6e4e-5244-a48c-c16c4d91dd3f","mechanism_event_label":"The oseltamivir record is a distinct-compound or preparation comparison; its biological effects are not assigned to isolated shikimic acid.","subject":{"id":"67ad4a8f-1bf6-59e5-90a6-97b7709024d3","slug":"shikimic-acid","display_name":"Shikimic acid","entity_type_key":"small_molecule"},"object":{"id":"ca29fbe2-9ef6-56c9-9a85-f884381de177","slug":"oseltamivir","display_name":"Oseltamivir","entity_type_key":"small_molecule"},"evidence_count":1,"mechanism_event":{"id":"ce19429d-6e4e-5244-a48c-c16c4d91dd3f","stable_key":"31b1baa4-4113-5541-b9e7-fe44a5253a07:scope-oseltamivir-event","event_type":"experimental_scope_comparison","label":"The oseltamivir record is a distinct-compound or preparation comparison; its biological effects are not assigned to isolated shikimic acid.","description":"**A manufacturing precursor is not the finished drug.** Shikimic acid has served as a starting scaffold for chemical manufacture of oseltamivir. Adding the drug’s other functional groups requires chemical synthesis; humans do not turn ingested shikimic acid into oseltamivir. Manufacturing and fermentation routes are industrial context, not antiviral evidence for shikimic acid. The 1997 neuraminidase-inhibitor chemistry paper and the 1998 practical synthesis report concern synthesized drug structures. [Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity.](https://pubmed.ncbi.nlm.nih.gov/16526129/) [Practical total synthesis of the anti-influenza drug GS-4104](https://doi.org/10.1021/jo980330q) [Metabolic engineering for microbial production of shikimic acid.](https://pubmed.ncbi.nlm.nih.gov/14642355/)","status":"provisional","compartment":null,"participants":[{"entity":{"id":"67ad4a8f-1bf6-59e5-90a6-97b7709024d3","slug":"shikimic-acid","display_name":"Shikimic acid","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"as reported","sequence_order":0,"notes":""},{"entity":{"id":"ca29fbe2-9ef6-56c9-9a85-f884381de177","slug":"oseltamivir","display_name":"Oseltamivir","entity_type_key":"small_molecule"},"role":"measured outcome","stoichiometry":null,"state_label":"not_reported","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary indexed abstract reviewed; full results, tables and supplements not independently extracted.\nBibliographic manufacturing context retained from draft; publisher full text unavailable in this review. No synthesis instructions or newly verified experimental quantities extracted.\nReview article, manufacturing background only; not affirmative primary experimental support.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Editorial identity/scope connection, not experimental causation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Unsigned navigation, not a human metabolic conversion or automatic ingredient attribution.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The oseltamivir record is a distinct-compound or preparation comparison; its biological effects are not assigned to isolated shikimic acid.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. | 1997 | DOI 10.1021/ja963036t | PMID 16526129 | https://pubmed.ncbi.nlm.nih.gov/16526129/ | https://doi.org/10.1021/ja963036t","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Metabolic engineering for microbial production of shikimic acid. | 2003 | DOI 10.1016/j.ymben.2003.09.001 | PMID 14642355 | https://pubmed.ncbi.nlm.nih.gov/14642355/ | https://doi.org/10.1016/j.ymben.2003.09.001","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Practical total synthesis of the anti-influenza drug GS-4104 | 1998 | DOI 10.1021/jo980330q | https://doi.org/10.1021/jo980330q","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference lines 43-43; exact primary location described in quoted passage where extracted.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"c6243d7c-ddf2-5851-827e-e2fed5143297","evidence_kind":"source_excerpt","locator":"Lines 43-43","start_line":43,"end_line":43,"excerpt":"**A manufacturing precursor is not the finished drug.** Shikimic acid has served as a starting scaffold for chemical manufacture of oseltamivir. Adding the drug’s other functional groups requires chemical synthesis; humans do not turn ingested shikimic acid into oseltamivir. Manufacturing and fermentation routes are industrial context, not antiviral evidence for shikimic acid. The 1997 neuraminidase-inhibitor chemistry paper and the 1998 practical synthesis report concern synthesized drug structures. [Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity.](https://pubmed.ncbi.nlm.nih.gov/16526129/) [Practical total synthesis of the anti-influenza drug GS-4104](https://doi.org/10.1021/jo980330q) [Metabolic engineering for microbial production of shikimic acid.](https://pubmed.ncbi.nlm.nih.gov/14642355/)","model_system":"Editorial identity/scope connection, not experimental causation.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Exact excerpt of the retained AI-assisted reviewed reference; primary sources are cited in primary_references and access scope is retained. Not a verbatim quotation from a primary paper.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"e6ae59de-0369-5c2f-8262-57d91302671c","stable_key":"import-31b1baa4-4113-5541-b9e7-fe44a5253a07","title":"Shikimic acid: detailed mechanisms of action (reviewed 5 October 2026)","document_type":"imported_text","citation_label":"Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication.","file_path":"","sha256":"95b1f9e9577661312d67f36e156d2e49326b207f296c1c0e801a5b007fd8e283","revision_id":"cd3237f1-131a-557d-84b5-7543259807b0","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}